Tempest Therapeutics (TPST) AI Stock Analysis

• Market Cap: $25.55M
• Dividend Yield: N/A
• Average Volume (3M): 72.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: N/A
• EPS Growth: -220.54%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 57
• Industry: Biotechnology
• EPS (TTM): -19.54
• Shares Outstanding: 3,655,015
• 10 Day Avg. Volume: 60,896
• 30 Day Avg. Volume: 72,569
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 0.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.

Positive Factors

Cost Savings

The recent drug supply agreement with Roche will supply atezolizumab for the upcoming Phase 3 study, providing a significant cost savings for the company.

Regulatory Advancements

The company received FDA clearance to proceed with a Phase 3 study of amezalpat in combination with current standard of care, providing a significant regulatory advancement.

Strategic Collaborations

Continued support from Roche is seen as further validation of amezalpat's potential in changing the 1L HCC treatment landscape.

Negative Factors

Financial Constraints

At the end of 2024, Tempest had cash and equivalents of $30.3 million, which will support start-up costs of the Phase III trial with amezalpat.

Funding Environment Challenges

Tempest is seeking to explore strategic alternatives to advance its pipeline of clinical stage oncology assets due to a dire funding environment and regulatory uncertainty.

Funding Needs

Tempest will still require a sizable cash infusion to fully support Phase 3 development, which is estimated to cost approximately $100 million.

Tempest Therapeutics Business Overview & Revenue Model

Company Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

How the Company Makes Money

Tempest Therapeutics makes money primarily through the development and potential commercialization of its therapeutic candidates. The company typically earns revenue through licensing agreements, collaboration partnerships, and milestone payments from larger pharmaceutical companies. These partnerships often involve joint development and commercialization efforts, where Tempest may receive upfront payments, research funding, and royalties from future sales of successfully developed drugs. Additionally, the company may secure funding from grants and public or private investments to support its research and clinical trials.

Tempest Therapeutics Financial Statement Overview

Summary

Tempest Therapeutics is in the growth stage typical for a biotech company, with no revenues and high expenditures leading to losses. Financial stability shows some signs of improvement, but heavy reliance on external financing and lack of operational cash flow remain significant risks.

Income Statement

Tempest Therapeutics has consistently recorded no revenue over the years, which is typical for many early-stage biotechnology companies. Although gross profit and net income are negative, showing the company is not yet profitable, it's important to note that this aligns with the industry's norm where R&D expenditures often outweigh revenues in initial phases.

Balance Sheet

The company's debt-to-equity ratio is somewhat high, indicating a reliance on debt financing. However, the equity ratio is improving, signaling potential strengthening of the financial position. Stockholders' equity has fluctuated over the years, with recent improvements, which is positive, but the overall financial stability remains a concern.

Cash Flow

Operating and free cash flows remain negative, reflecting ongoing cash burn typical for the sector. The company has managed to secure financing consistently, which has supported cash flow but highlights reliance on external funding. The lack of any significant positive cash flow from operations poses a risk.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-381.00K	-1.81M	-1.27M	-815.00K
	EBIT
0.00	-29.16M	-34.64M	-26.99M	-19.30M
	EBITDA
0.00	-28.78M	-32.28M	-25.72M	-18.39M
	Net Income Common Stockholders
-41.84M	-29.49M	-36.78M	-29.55M	-19.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
30.27M	39.23M	31.23M	51.83M	18.82M
	Total Assets
41.49M	51.60M	46.09M	73.24M	22.86M
	Total Debt
15.37M	20.66M	22.11M	18.54M	2.44M
	Net Debt
-14.90M	-18.57M	-9.12M	-33.29M	-16.38M
	Total Liabilities
22.36M	24.84M	27.98M	37.12M	91.66M
	Stockholders Equity
19.13M	26.77M	18.11M	36.12M	-68.79M
Cash Flow		Free Cash Flow
-33.46M	-27.53M	-31.63M	-26.09M	-19.07M
	Operating Cash Flow
-33.03M	-27.36M	-31.07M	-25.96M	-19.02M
	Investing Cash Flow
-435.00K	-170.00K	-562.00K	-97.00K	-6.00K
	Financing Cash Flow
24.50M	35.60M	11.40M	59.06M	34.60M

Tempest Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 6.99 is below the 20-day moving average (MA) of 7.19, below the 50-day MA of 9.18, and below the 200-day MA of 13.41, indicating a bearish trend. The MACD of -0.57 indicates Negative momentum. The RSI at 39.21 is Neutral, neither overbought nor oversold. The STOCH value of 19.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.

Tempest Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%
PASG	44 Neutral	$24.55M	―	-75.07%	―	―	42.39%
QTTB	41 Neutral	$20.00M	―	-121.36%	―	-100.00%	91.45%
PYPD	41 Neutral	$28.43M	―	-1038.73%	―	―	34.97%
TPST	39 Underperform	$25.55M	―	-182.35%	―	―	-220.54%
GBIO	38 Underperform	$29.21M	―	-91.02%	―	236.92%	-0.57%
ANVS	35 Underperform	$31.37M	―	-3159.09%	―	―	68.75%

Tempest Therapeutics Corporate Events

Tempest Therapeutics Terminates Loan Agreement with Oxford

On August 8, 2025, Tempest Therapeutics, Inc. repaid $3.5 million to fully satisfy its obligations under a Loan and Security Agreement with Oxford Finance LLC, effectively terminating the agreement and releasing all associated liens and security interests. Earlier, on April 9, 2025, the company announced plans to explore strategic alternatives, including potential mergers or partnerships, to advance its clinical-stage programs and enhance stockholder value, particularly focusing on its promising oncology assets such as amezalpat and TPST-1495.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.

Tempest Therapeutics faces typical challenges for a biotech firm in its early stages, with no revenue and high R&D expenses leading to financial losses. While there are signs of financial improvement, the stock’s bearish trend and high volatility pose risks. The negative P/E ratio highlights unprofitability, with no dividend yield as the company focuses on growth.

To see Spark’s full report on TPST stock, click here.